DPP4 and breast angiosarcoma: However, while DPP4 inhibition proved effective to reduce levels of GOT (PBS Controls: 808.0 ± 251.5 U/L; Sitagliptin 553.2 ± 150.7 U/L, p < 0.001) and Bilirubin (PBS Controls: 186.2 ± 73.74 U/L; Sitagliptin 95.1 ± 22.26 U/L, p < 0.001) compared to controls (Fig. 4D), no significant impact on survival, weight development or clinical BA score was observed (Fig. 4B + C).